These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35058126)

  • 1. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
    Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
    J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff.
    Uwamino Y; Kurafuji T; Sato Y; Tomita Y; Shibata A; Tanabe A; Yatabe Y; Noguchi M; Arai T; Ohno A; Yokota H; Yamasawa W; Uno S; Nishimura T; Hasegawa N; Saya H; Wakui M; Murata M;
    Vaccine; 2022 Feb; 40(7):1019-1025. PubMed ID: 35033389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
    Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
    Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study.
    Urakawa R; Isomura ET; Matsunaga K; Kubota K; Ike M
    BMC Infect Dis; 2022 Feb; 22(1):179. PubMed ID: 35197017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
    Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
    J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
    Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
    mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
    Naito T; Tsuchida N; Kusunoki S; Kaneko Y; Tobita M; Hori S; Ito S
    Expert Rev Vaccines; 2022 Sep; 21(9):1319-1329. PubMed ID: 35763290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Chapin-Bardales J; Myers T; Gee J; Shay DK; Marquez P; Baggs J; Zhang B; Licata C; Shimabukuro TT
    Vaccine; 2021 Nov; 39(48):7066-7073. PubMed ID: 34763946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study.
    Bareiß A; Uzun G; Mikus M; Becker M; Althaus K; Schneiderhan-Marra N; Fürstberger A; Schwab JD; Kestler HA; Holderried M; Martus P; Schenke-Layland K; Bakchoul T
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers.
    Lee DY; Kang DY; Kim E; Lee SJ; Baek JH; Lee JS; Park MY; Im JH
    Medicine (Baltimore); 2023 Mar; 102(11):e33236. PubMed ID: 36930126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital.
    Valera-Rubio MM; Sierra-Torres MIM; Castillejo García RR; Cordero-Ramos JJ; López-Márquez MRM; Cruz-Salgado ÓO; Calleja-Hernández MÁM
    Expert Rev Vaccines; 2022 Apr; 21(4):533-540. PubMed ID: 34986076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Sex and Age on mRNA COVID-19 Vaccine-Related Side Effects in Japan.
    Mori M; Yokoyama A; Shichida A; Sasuga K; Maekawa T; Moriyama T
    Microbiol Spectr; 2022 Dec; 10(6):e0130922. PubMed ID: 36314943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.